Oxford researchers have reportedly received promising news about their coronavirus vaccine
The University of Oxford's Jenner Institute made waves last week when U.K. Health Minister Matt Hancock announced a team is starting trials on a potential coronavirus vaccine of which there could be a million doses by September, which is, in vaccine terms, incredibly fast. There's still a long way to go before determining if the vaccine is viable, but The New York Times reports there's promising news that it may be both safe and effective.
Scientists at the National Institute of Health's Rocky Mountain Laboratory in Montana tested the Oxford vaccine on six rhesus macaques monkeys. The monkeys were exposed to heavy quantities of the coronavirus, an amount that had previously sickened other monkeys in the lab, before receiving a single dose of the vaccine. More than four weeks later all six monkeys were healthy, Dr. Vincent Munster, the researcher who conducted the test, told the Times. That doesn't mean it will work the same way in humans, but Munster noted the rhesus macaque is "pretty much the closest thing we have to humans," so the results are at least promising.
One thing that could hold trials back, however, is if other measures to curb the pandemic, such as social distancing, work too well, the Times reports. In order to get a real sense of a vaccine's efficacy, tests need to be conducted in places where the virus is spreading swiftly. Read more at The New York Times.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Critics’ choice: Watering holes for gourmandsFeature An endless selection of Mexican spirits, a Dublin-inspired bar, and an upscale Baltimore pub
-
Argentinian beef is at the center of American farmers’ woesThe Explainer ‘It feels like a slap in the face to rural America,’ said one farmer
-
‘Businesses that lose money and are uncompetitive won’t survive’Instant Opinion Opinion, comment and editorials of the day
-
Covid-19 mRNA vaccines could help fight cancerUnder the radar They boost the immune system
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
The new Stratus Covid strain – and why it’s on the riseThe Explainer ‘No evidence’ new variant is more dangerous or that vaccines won’t work against it, say UK health experts
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Measles cases surge to 33-year highSpeed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, changeSpeed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
